Drug class
Sphingosine 1-Phos Recep Mod for Mult.Sclerosis/Inflam.Bowel
The exact phrase represents a specific compendial or formulary classification label rather than a standalone standard pharmacological class name. Read more about Sphingosine 1-Phos Recep Mod for Mult.Sclerosis/Inflam.Bowel
30 drugs in this class 22 manufacturers
Drugs in Sphingosine 1-Phos Recep Mod for Mult.Sclerosis/Inflam.Bowel
ZEPOSIA STARTER KIT (28-DAY) (ozanimod hydrochloride)
VELSIPITY (etrasimod arginine)
FINGOLIMOD (fingolimod HCl)
FINGOLIMOD (fingolimod HCl)
FINGOLIMOD (fingolimod HCl)
PONVORY (ponesimod)
FINGOLIMOD (fingolimod HCl)
FINGOLIMOD (fingolimod HCl)
The exact phrase represents a specific compendial or formulary classification label rather than a standalone standard pharmacological class name.
It refers to sphingosine 1-phosphate (S1P) receptor modulators—such as ozanimod—categorized by their therapeutic indications in relapsing forms of multiple sclerosis and inflammatory bowel disease, specifically moderately to severely active ulcerative colitis.
These agents work by binding to selective S1P receptor subtypes on lymphocytes, which induces receptor internalization and prevents the egress of autoreactive T and B cells from secondary lymphoid tissues into circulation.
By sequestering lymphocytes, they reduce lymphocyte infiltration into the central nervous system and the intestinal mucosa, thereby mitigating autoimmune neuroinflammation and chronic gut mucosal damage.
-
fda.gov
The exact phrase represents a specific compendial or formulary classification label rather than a standalone standard pharmacological class name It refers to sphingosine 1-phosphate (S1P) receptor modulators—such as ozanimod—categorized by their therapeutic indications in relapsing forms of multiple sclerosis and inflammatory bowel disease, specifically moderately to severely active ulcerative colitis
-
nih.gov
The exact phrase represents a specific compendial or formulary classification label rather than a standalone standard pharmacological class name It refers to sphingosine 1-phosphate (S1P) receptor modulators—such as ozanimod—categorized by their therapeutic indications in relapsing forms of multiple sclerosis and inflammatory bowel disease, specifically moderately to severely active ulcerative colitis These agents work by binding to selective S1P receptor subtypes on lymphocytes, which induces r...
-
gastroenterologyandhepatology.net
These agents work by binding to selective S1P receptor subtypes on lymphocytes, which induces receptor internalization and prevents the egress of autoreactive T and B cells from secondary lymphoid tissues into circulation By sequestering lymphocytes, they reduce lymphocyte infiltration into the central nervous system and the intestinal mucosa, thereby mitigating autoimmune neuroinflammation and chronic gut mucosal damage
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.